San Francisco, CA: The administration of the cannabinoid THC selectively inhibits the proliferation of malignant cancer cells more effectively than does the use of a synthetic cannabinoid agent, according to clinical trial data published in the August issue of the Journal of Neurooncology.
Researchers at the California Pacific Medical Center Research Institute reported that the administration of THC on human glioblastoma multiforme (brain tumor) cell lines decreased the proliferation of malignant cells and induced apoptosis (programmed cell death) more rapidly than did the administration of the cannabis receptor agonist WIN-55,212-2. Researchers also noted that THC selectively targeted malignant cells while ignoring healthy ones in a more profound manner than did the synthetic agonist.
Previous trials have found that cannabinoids selectively induce tumor regression in rodents and in human cells, including the inhibition of lung carcinoma, glioma (brain tumors), lymphoma/leukemia, skin carcinoma, prostate cancer, and breast cancer.
For more information, please contact Paul Armentano, NORML Senior Policy Analyst, at (202) 483-5500. Full text of the study, “Cannabinoids selectively inhibit proliferation and induce cell death of cultured human glioblastoma multiforme cells,” appears in the August issue of the Journal of Neurooncology.